Oruka Therapeutics Raises $700 Million Following Breakthrough Psoriasis Trial Results

Menlo Park, Wednesday, 29 April 2026.
Capitalizing on clinical trials where 63.5% of patients achieved complete skin clearance, Oruka Therapeutics upsized its public offering to $700 million to challenge existing blockbuster psoriasis treatments.